1. JAK/STAT Signaling Stem Cell/Wnt Apoptosis
  2. STAT Apoptosis
  3. YN11

YN11 is a STAT3 inhibitor (Kd=11.9 μM). YN11 directly binds to the SH2 domain of STAT3, inhibits the phosphorylation of STAT3, and reduces the expression of downstream target proteins. YN11 induces cell cycle arrest, promotes apoptosis, and inhibits cell invasion and migration in prostate cancer cells. YN11 suppresses tumor growth in a prostate cancer xenograft mouse model. YN11 does not cause significant body weight loss or obvious histopathological changes in major organs in xenograft mice. YN11 is applicable to relevant research on prostate cancer.

For research use only. We do not sell to patients.

YN11

YN11 Chemical Structure

CAS No. : 3118507-43-7

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products

View All STAT Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

YN11 is a STAT3 inhibitor (Kd=11.9 μM). YN11 directly binds to the SH2 domain of STAT3, inhibits the phosphorylation of STAT3, and reduces the expression of downstream target proteins. YN11 induces cell cycle arrest, promotes apoptosis, and inhibits cell invasion and migration in prostate cancer cells. YN11 suppresses tumor growth in a prostate cancer xenograft mouse model. YN11 does not cause significant body weight loss or obvious histopathological changes in major organs in xenograft mice. YN11 is applicable to relevant research on prostate cancer[1].

IC50 & Target

STAT3

11.9 μM (Ki)

In Vitro

YN11 (24 h) strongly suppresses STAT3-mediated transcriptional activity in IL-6-stimulated HEK293T cells with an IC50 of 0.17 μM[1].
YN11 (72 h) potently inhibits the proliferation of DU145 and 22RV1 prostate cancer cells with IC50 values of 23 nM and 389 nM, respectively, and shows high selectivity for cancer cells over normal BEAS-2B cells with an SI of 82[1].
YN11 (0.01-0.1 μM (DU145), 0.1-1 μM (22RV1); 24 h) dose-dependently inhibits STAT3 phosphorylation in DU145 and 22RV1 prostate cancer cells without altering total STAT3 levels, and downregulates downstream STAT3 target proteins Bcl-2 and Cyclin D1, while showing specificity for STAT3 over STAT1 and STAT5[1].
YN11 (0.01-0.1 μM (DU145), 0.1-1 μM (22RV1); 24 h) induces S-phase cell cycle arrest in DU145 prostate cancer cells and G2/M-phase cell cycle arrest in 22RV1 prostate cancer cells in a dose-dependent manner after 24 h of incubation[1].
YN11 (0.01-0.1 μM (DU145), 0.1-1 μM (22RV1); 24 h initial treatment, 24 h invasion incubation) dose-dependently inhibits the invasion of DU145 and 22RV1 prostate cancer cells after 24 h of initial treatment and a subsequent 24 h invasion incubation[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: DU145 and 22RV1 prostate cancer cells
Concentration: 0.01-0.1 μM (DU145 cells); 0.1-1 μM (22RV1 cells)
Incubation Time: 24 h
Result: Reduced the level of phosphorylated STAT3 (p-STAT3) in a dose-dependent manner in both DU145 and 22RV1 cells, without affecting total STAT3 protein levels.
Reduced the levels of downstream target proteins Bcl-2 and Cyclin D1 in a dose-dependent manner in both cell lines.
Did not affect expression or phosphorylation of STAT1 or STAT5.

Apoptosis Analysis[1]

Cell Line: DU145 and 22RV1 prostate cancer cells
Concentration: 0.01-0.1 μM (DU145 cells); 0.1-1 μM (22RV1 cells)
Incubation Time: 24 h
Result: Induced apoptosis in a dose-dependent manner in both cell lines.
0.1 μM YN11 increased DU145 cell apoptosis to 29.11%.
1 μM YN11 increased 22RV1 cell apoptosis to 31.94%.

Cell Cycle Analysis[1]

Cell Line: DU145 and 22RV1 prostate cancer cells
Concentration: 0.01-0.1 μM (DU145 cells); 0.1-1 μM (22RV1 cells)
Incubation Time: 24 h
Result: Induced S-phase cell cycle arrest in a dose-dependent manner in DU145 cells, with 0.1 μM increasing the proportion of S-phase cells to 28.68%.
Induced G2/M-phase cell cycle arrest in a dose-dependent manner in 22RV1 cells, with 1 μM increasing the proportion of G2/M-phase cells to 33.33%.
In Vivo

YN11 (20 mg/kg; i.p.; once every other day; 17 days) achieves a 50.60% tumor growth inhibition rate in DU145 prostate cancer xenografts, inhibits STAT3 signaling in tumor tissue, and causes no detectable toxicity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude mice with Prostate cancer (male, 5 weeks old, subcutaneous xenograft model)[1]
Dosage: 20 mg/kg
Administration: i.p.; once every other day; 17 days
Result: Reduced relative tumor volume and tumor weight, resulting in a tumor growth inhibition (TGI) rate of 50.60%.
Significantly suppressed STAT3 phosphorylation, and reduced Bcl-2 and Cyclin D1 expression in tumor tissues.
Caused no body weight loss, and histopathological analysis of major organs (liver, heart, kidney, lung, spleen) showed no observable pathological injuries.
Molecular Weight

510.52

Formula

C25H22N2O8S

CAS No.
SMILES

O=C(C1=C2OC(C(N3CCN(S(=O)(C4=CC=C(OC)C(OC)=C4)=O)CC3)=O)=C1)C5=C(C2=O)C=CC=C5

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
YN11
Cat. No.:
HY-182288
Quantity:
MCE Japan Authorized Agent: